Search :
Sign in or Register  
Welcome Sign in or Don't have an account?Register

Mouse Anti-KRT5 Recombinant Antibody (LP34) (CBMAB-C3182WJ)


See all KRT5 antibodies
Online Inquiry

Summary

Host Animal
Mouse
Specificity
Human
Clone
LP34
Antibody Isotype
IgG1
Application
IHC-Fr

Basic Information

Specificity
Human
Antibody Isotype
IgG1
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
Keratin 5
Introduction
The protein encoded by this gene is a member of the keratin gene family. The type II cytokeratins consist of basic or neutral proteins which are arranged in pairs of heterotypic keratin chains coexpressed during differentiation of simple and stratified epithelial tissues. This type II cytokeratin is specifically expressed in the basal layer of the epidermis with family member KRT14. Mutations in these genes have been associated with a complex of diseases termed epidermolysis bullosa simplex. The type II cytokeratins are clustered in a region of chromosome 12q12-q13. [provided by RefSeq, Jul 2008]
Entrez Gene ID
3852
UniProt ID
P13647
Alternative Names
Keratin 5; Keratin 5 (Epidermolysis Bullosa Simplex, Dowling-Meara/Kobner/Weber-Cockayne Types); Epidermolysis Bullosa Simplex 2 Dowling-Meara/Kobner/Weber-Cockayne Types; Type-II Keratin Kb5; Keratin 5, Type II; Cytokeratin-5; CK-5; K5; Keratin, Type II Cytoskeletal 5;
Biological Process
Epidermis developmentManual Assertion Based On ExperimentTAS:ProtInc
Cellular Location
Cytoplasm
Cytosol
Extracellular exosome
Intermediate filament
Keratin filament
Membrane
Nucleus
Involvement in disease
Epidermolysis bullosa simplex, autosomal recessive 1 (EBSB1):
A form of epidermolysis bullosa, a genodermatosis characterized by recurrent blistering and cleavage within basal keratinocytes, fragility of the skin and mucosal epithelia, and erosions caused by minor mechanical trauma.
Epidermolysis bullosa simplex, Dowling-Meara type (DM-EBS):
A severe form of intraepidermal epidermolysis bullosa characterized by generalized herpetiform blistering, milia formation, dystrophic nails, and mucous membrane involvement.
Epidermolysis bullosa simplex, with migratory circinate erythema (EBSMCE):
A form of intraepidermal epidermolysis bullosa characterized by unusual migratory circinate erythema. Skin lesions appear from birth primarily on the hands, feet, and legs but spare nails, ocular epithelia and mucosae. Lesions heal with brown pigmentation but no scarring. Electron microscopy findings are distinct from those seen in the DM-EBS, with no evidence of tonofilament clumping.
Epidermolysis bullosa simplex, Weber-Cockayne type (WC-EBS):
A form of intraepidermal epidermolysis bullosa characterized by blistering limited to palmar and plantar areas of the skin.
Epidermolysis bullosa simplex, Koebner type (K-EBS):
A form of intraepidermal epidermolysis bullosa characterized by generalized skin blistering. The phenotype is not fundamentally distinct from the Dowling-Meara type, although it is less severe.
Epidermolysis bullosa simplex, with mottled pigmentation (MP-EBS):
A form of intraepidermal epidermolysis bullosa characterized by blistering at acral sites and 'mottled' pigmentation of the trunk and proximal extremities with hyper- and hypopigmentation macules.
Dowling-Degos disease 1 (DDD1):
An autosomal dominant genodermatosis. Affected individuals develop a postpubertal reticulate hyperpigmentation that is progressive and disfiguring, and small hyperkeratotic dark brown papules that affect mainly the flexures and great skin folds. Patients usually show no abnormalities of the hair or nails.
More Infomation

Thomsen, C., Blok-Husum, L., Georgsen, J. B., Steiniche, T., & Vyberg, M. (2023). Keratin 5 in Lung Cancer Specimens: Comparison of Four Antibody Clones and KRT5 mRNA-ISH. Applied Immunohistochemistry & Molecular Morphology, 10-1097.

Ho, M., Thompson, B., Fisk, J. N., Nebert, D. W., Bruford, E. A., Vasiliou, V., & Bunick, C. G. (2022). Update of the keratin gene family: evolution, tissue-specific expression patterns, and relevance to clinical disorders. Human Genomics, 16(1), 1-21.

Cohen, E., Johnson, C., Redmond, C. J., Nair, R. R., & Coulombe, P. A. (2022). Revisiting the significance of keratin expression in complex epithelia. Journal of Cell Science, 135(20), jcs260594.

Chen, F., Yao, L., Zhang, X., Gu, Y., Yu, H., Yao, Z., ... & Li, M. (2021). Damaged keratin filament network caused by KRT5 mutations in localized recessive epidermolysis bullosa simplex. Frontiers in Genetics, 12, 736610.

Masuda, N., Murakami, K., Kita, Y., Hamada, A., Kamada, M., Teramoto, Y., ... & Kobayashi, T. (2020). Trp53 mutation in keratin 5 (Krt5)-expressing basal cells facilitates the development of basal squamous-like invasive bladder cancer in the chemical carcinogenesis of mouse bladder. The American Journal of Pathology, 190(8), 1752-1762.

Yalici‐Armagan, B., Kabacam, S., Taskiran, Z. E., Gököz, Ö., Utine, G. E., & Ersoy‐Evans, S. (2020). A novel mutation of keratin 5 in epidermolysis bullosa simplex with migratory circinate erythema. Pediatric Dermatology, 37(2), 358-361.

Vahidnezhad, H., Youssefian, L., Daneshpazhooh, M., Mahmoudi, H., Kariminejad, A., Fischer, J., ... & Uitto, J. (2019). Biallelic KRT5 mutations in autosomal recessive epidermolysis bullosa simplex, including a complete human keratin 5 “knock-out”. Matrix Biology, 83, 48-59.

Khani, P., Ghazi, F., Zekri, A., Nasri, F., Behrangi, E., Aghdam, A. M., & Mirzaei, H. (2019). Keratins and epidermolysis bullosa simplex. Journal of cellular physiology, 234(1), 289-297.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-KRT5 Recombinant Antibody (LP34)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Learn more

Documents

Request bulk or custom quoteOnline Inquiry
Second antibody and isotype control

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Online Inquiry